{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:42:39Z","timestamp":1790775759838,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T00:00:00Z","timestamp":1645142400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T00:00:00Z","timestamp":1645142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["RF1 AG051495"],"award-info":[{"award-number":["RF1 AG051495"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["RF1 AG051495"],"award-info":[{"award-number":["RF1 AG051495"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["RF1 AG050597"],"award-info":[{"award-number":["RF1 AG050597"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["U54 AG054345"],"award-info":[{"award-number":["U54 AG054345"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["K01 AG054753"],"award-info":[{"award-number":["K01 AG054753"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R03 AG063250"],"award-info":[{"award-number":["R03 AG063250"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["RF1 AG074566"],"award-info":[{"award-number":["RF1 AG074566"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["RF1 AG074566"],"award-info":[{"award-number":["RF1 AG074566"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["RF1 AG074566"],"award-info":[{"award-number":["RF1 AG074566"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR002529"],"award-info":[{"award-number":["UL1TR002529"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000092","name":"U.S. National Library of Medicine","doi-asserted-by":"publisher","award":["R01 LM012535"],"award-info":[{"award-number":["R01 LM012535"]}],"id":[{"id":"10.13039\/100000092","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Genome Med"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Alzheimer\u2019s disease (AD) is characterized by robust microgliosis and phenotypic changes that accompany disease pathogenesis. Accumulating evidence from genetic studies suggests the importance of phospholipase C \u03b3 2 (PLCG2) in late-onset AD (LOAD) pathophysiology. However, the role of\n                      <jats:italic>PLCG2<\/jats:italic>\n                      in AD is still poorly understood.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Using bulk RNA-Seq (\n                      <jats:italic>N<\/jats:italic>\n                      =1249) data from the Accelerating Medicines Partnership-Alzheimer\u2019s Disease Consortium (AMP-AD), we investigated whether\n                      <jats:italic>PLCG2<\/jats:italic>\n                      expression increased in the brains of LOAD patients. We also evaluated the relationship between\n                      <jats:italic>PLCG2<\/jats:italic>\n                      expression levels, amyloid plaque density, and expression levels of microglia specific markers (\n                      <jats:italic>AIF1 and TMEM119<\/jats:italic>\n                      ). Finally, we investigated the longitudinal changes of\n                      <jats:italic>PLCG2<\/jats:italic>\n                      expression in the 5xFAD mouse model of AD. To further understand the role of\n                      <jats:italic>PLCG2<\/jats:italic>\n                      in different signaling pathways, differential gene expression and co-expression network analyses were performed using bulk RNA-Seq and microglial single-cell RNA-Seq data. To substantiate the human analyses, we performed differential gene expression analysis on wild-type (WT) and inactivated\n                      <jats:italic>Plcg2<\/jats:italic>\n                      mice and used immunostaining to determine if the differentially expressed genes\/pathways were altered by microglial cell coverage or morphology.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We observed significant upregulation of\n                      <jats:italic>PLCG2<\/jats:italic>\n                      expression in three brain regions of LOAD patients and significant positive correlation of\n                      <jats:italic>PLCG2<\/jats:italic>\n                      expression with amyloid plaque density. These findings in the human brain were validated in the 5xFAD amyloid mouse model, which showed disease progression-dependent increases in\n                      <jats:italic>Plcg2<\/jats:italic>\n                      expression associated with amyloid pathology. Of note, increased\n                      <jats:italic>Plcg2<\/jats:italic>\n                      expression levels in 5xFAD mice were abolished by reducing microglia. Furthermore, using bulk RNA-Seq data, we performed differential expression analysis by comparing cognitively normal older adults (CN) with 75th percentile (high) and 25th percentile (low)\n                      <jats:italic>PLCG2<\/jats:italic>\n                      gene expression levels to identify pathways related to inflammation and the inflammatory response. The findings in the human brain were validated by differential expression analyses between WT and\n                      <jats:italic>plcg2<\/jats:italic>\n                      inactivated mice.\n                      <jats:italic>PLCG2<\/jats:italic>\n                      co-expression network analysis of microglial single-cell RNA-Seq data identified pathways related to the inflammatory response including regulation of I-kappaB\/NF-kappa B signaling and response to lipopolysaccharide.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Our results provide further evidence that\n                      <jats:italic>PLCG2<\/jats:italic>\n                      plays an important role in AD pathophysiology and may be a potential target for microglia-targeted AD therapies.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13073-022-01022-0","type":"journal-article","created":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T08:03:32Z","timestamp":1645171412000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":95,"title":["PLCG2 is associated with the inflammatory response and is induced by amyloid plaques in Alzheimer\u2019s disease"],"prefix":"10.1186","volume":"14","author":[{"given":"Andy P.","family":"Tsai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanpeng","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter Bor-Chian","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan J.","family":"Messenger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad T.","family":"Casali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Moutinho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunlong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian L.","family":"Oblak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce T.","family":"Lamb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary E.","family":"Landreth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie J.","family":"Bissel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwangsik","family":"Nho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,18]]},"reference":[{"key":"1022_CR1","doi-asserted-by":"publisher","first-page":"307","DOI":"10.2147\/CIA.S11718","volume":"5","author":"AT Isik","year":"2010","unstructured":"Isik AT. Late onset Alzheimer\u2019s disease in older people. Clin Interv Aging. 2010;5:307\u201311.","journal-title":"Clin Interv Aging"},{"key":"1022_CR2","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jsbmb.2016.03.012","volume":"160","author":"BC Riedel","year":"2016","unstructured":"Riedel BC, Thompson PM, Brinton RD. Age, APOE and sex: triad of risk of Alzheimer\u2019s disease. J Steroid Biochem Mol Biol. 2016;160:134\u201347.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"1022_CR3","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/s41467-019-14279-8","volume":"11","author":"EM Reiman","year":"2020","unstructured":"Reiman EM, Arboleda-Velasquez JF, Quiroz YT, Huentelman MJ, Beach TG, Caselli RJ, et al. Exceptionally low likelihood of Alzheimer\u2019s dementia in APOE2 homozygotes from a 5,000-person neuropathological study. Nat Commun. 2020;11:667.","journal-title":"Nat Commun"},{"key":"1022_CR4","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.neuron.2009.06.026","volume":"63","author":"J Kim","year":"2009","unstructured":"Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer\u2019s disease. Neuron. 2009;63:287\u2013303.","journal-title":"Neuron"},{"key":"1022_CR5","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1002\/ana.21915","volume":"67","author":"MM Corrada","year":"2010","unstructured":"Corrada MM, Brookmeyer R, Paganini-Hill A, Berlau D, Kawas CH. Dementia incidence continues to increase with age in the oldest old: the 90+ study. Ann Neurol. 2010;67:114\u201321.","journal-title":"Ann Neurol"},{"key":"1022_CR6","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/s41588-019-0358-2","volume":"51","author":"BW Kunkle","year":"2019","unstructured":"Kunkle BW, Grenier-Boley B, Sims R, Bis JC, Damotte V, Naj AC, et al. Genetic meta-analysis of diagnosed Alzheimer\u2019s disease identifies new risk loci and implicates Abeta, tau, immunity and lipid processing. Nat Genet. 2019;51:414\u201330.","journal-title":"Nat Genet"},{"key":"1022_CR7","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13024-017-0184-x","volume":"12","author":"AG Efthymiou","year":"2017","unstructured":"Efthymiou AG, Goate AM. Late onset Alzheimer\u2019s disease genetics implicates microglial pathways in disease risk. Mol Neurodegener. 2017;12:43.","journal-title":"Mol Neurodegener"},{"key":"1022_CR8","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.biopsych.2014.05.006","volume":"77","author":"CM Karch","year":"2015","unstructured":"Karch CM, Goate AM. Alzheimer\u2019s disease risk genes and mechanisms of disease pathogenesis. Biol Psychiatry. 2015;77:43\u201351.","journal-title":"Biol Psychiatry"},{"key":"1022_CR9","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1038\/ng.3916","volume":"49","author":"R Sims","year":"2017","unstructured":"Sims R, van der Lee SJ, Naj AC, Bellenguez C, Badarinarayan N, Jakobsdottir J, et al. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer\u2019s disease. Nat Genet. 2017;49:1373\u201384.","journal-title":"Nat Genet"},{"key":"1022_CR10","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13195-019-0469-0","volume":"11","author":"L Magno","year":"2019","unstructured":"Magno L, Lessard CB, Martins M, Lang V, Cruz P, Asi Y, et al. Alzheimer\u2019s disease phospholipase C-gamma-2 (PLCG2) protective variant is a functional hypermorph. Alzheimers Res Ther. 2019;11:16.","journal-title":"Alzheimers Res Ther"},{"key":"1022_CR11","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2020105603","volume":"40","author":"E Maguire","year":"2021","unstructured":"Maguire E, Menzies GE, Phillips T, Sasner M, Williams HM, Czubala MA, et al. PIP2 depletion and altered endocytosis caused by expression of Alzheimer\u2019s disease-protective variant PLCgamma2 R522. EMBO J. 2021;40:e105603.","journal-title":"EMBO J"},{"key":"1022_CR12","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1006\/geno.1994.1533","volume":"23","author":"D Hernandez","year":"1994","unstructured":"Hernandez D, Egan SE, Yulug IG, Fisher EM. Mapping the gene that encodes phosphatidylinositol-specific phospholipase C-gamma 2 in the human and the mouse. Genomics. 1994;23:504\u20137.","journal-title":"Genomics"},{"key":"1022_CR13","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13024-020-00402-7","volume":"15","author":"M Takalo","year":"2020","unstructured":"Takalo M, Wittrahm R, Wefers B, Parhizkar S, Jokivarsi K, Kuulasmaa T, et al. The Alzheimer\u2019s disease-associated protective Plc\u03b32-P522R variant promotes immune functions. Mol Neurodegener. 2020;15:52.","journal-title":"Mol Neurodegener"},{"key":"1022_CR14","doi-asserted-by":"crossref","unstructured":"Hajicek N, Keith NC, Siraliev-Perez E, Temple BR, Huang W, Zhang Q, Harden TK, Sondek J. Structural basis for the activation of PLC-gamma isozymes by phosphorylation and cancer-associated mutations. Elife.\u00a02019;8.","DOI":"10.7554\/eLife.51700"},{"key":"1022_CR15","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/s41593-020-0650-6","volume":"23","author":"BJ Andreone","year":"2020","unstructured":"Andreone BJ, Przybyla L, Llapashtica C, Rana A, Davis SS, van Lengerich B, et al. Alzheimer\u2019s-associated PLC\u03b32 is a signaling node required for both TREM2 function and the inflammatory response in human microglia. Nat Neurosci. 2020;23:927\u201338.","journal-title":"Nat Neurosci"},{"key":"1022_CR16","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13024-021-00436-5","volume":"16","author":"L Magno","year":"2021","unstructured":"Magno L, Bunney TD, Mead E, Svensson F, Bictash MN. TREM2\/PLC\u03b32 signalling in immune cells: function, structural insight, and potential therapeutic modulation. Mol Neurodegener. 2021;16:22.","journal-title":"Mol Neurodegener"},{"key":"1022_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/sdata.2018.142","volume":"5","author":"PL De Jager","year":"2018","unstructured":"De Jager PL, Ma Y, McCabe C, Xu J, Vardarajan BN, Felsky D, et al. A multi-omic atlas of the human frontal cortex for aging and Alzheimer\u2019s disease research. Sci Data. 2018;5:180142.","journal-title":"Sci Data"},{"key":"1022_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/sdata.2016.89","volume":"3","author":"M Allen","year":"2016","unstructured":"Allen M, Carrasquillo MM, Funk C, Heavner BD, Zou F, Younkin CS, et al. Human whole genome genotype and transcriptome data for Alzheimer\u2019s and other neurodegenerative diseases. Sci Data. 2016;3:160089.","journal-title":"Sci Data"},{"key":"1022_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/sdata.2018.185","volume":"5","author":"M Wang","year":"2018","unstructured":"Wang M, Beckmann ND, Roussos P, Wang E, Zhou X, Wang Q, et al. The Mount Sinai cohort of large-scale genomic, transcriptomic and proteomic data in Alzheimer\u2019s disease. Sci Data. 2018;5:180185.","journal-title":"Sci Data"},{"key":"1022_CR20","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1212\/WNL.43.1_Part_1.241-a","volume":"43","author":"JC Morris","year":"1993","unstructured":"Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412\u20134.","journal-title":"Neurology"},{"key":"1022_CR21","doi-asserted-by":"publisher","first-page":"S161","DOI":"10.3233\/JAD-179939","volume":"64","author":"DA Bennett","year":"2018","unstructured":"Bennett DA, Buchman AS, Boyle PA, Barnes LL, Wilson RS, Schneider JA. Religious orders study and rush memory and aging project. J Alzheimers Dis. 2018;64:S161\u201389.","journal-title":"J Alzheimers Dis"},{"key":"1022_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2021.105303","volume":"153","author":"AP Tsai","year":"2021","unstructured":"Tsai AP, Lin PB, Dong C, Moutinho M, Casali BT, Liu Y, et al. INPP5D expression is associated with risk for Alzheimer\u2019s disease and induced by plaque-associated microglia. Neurobiol Dis. 2021;153:105303.","journal-title":"Neurobiol Dis"},{"key":"1022_CR23","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47.","journal-title":"Nucleic Acids Res"},{"key":"1022_CR24","doi-asserted-by":"publisher","first-page":"6129","DOI":"10.1038\/s41467-020-19737-2","volume":"11","author":"M Olah","year":"2020","unstructured":"Olah M, Menon V, Habib N, Taga MF, Ma Y, Yung CJ, et al. Single cell RNA sequencing of human microglia uncovers a subset associated with Alzheimer\u2019s disease. Nat Commun. 2020;11:6129.","journal-title":"Nat Commun"},{"issue":"3573-3587","key":"1022_CR25","volume":"184","author":"Y Hao","year":"2021","unstructured":"Hao Y, Hao S, Andersen-Nissen E, Mauck WM 3rd, Zheng S, Butler A, et al. Integrated analysis of multimodal single-cell data. Cell. 2021;184(3573-3587):e3529.","journal-title":"Cell"},{"key":"1022_CR26","doi-asserted-by":"crossref","unstructured":"Huynh-Thu VA, Irrthum A, Wehenkel L, Geurts P. Inferring regulatory networks from expression data using tree-based methods. PLoS One.\u00a02010;5.","DOI":"10.1371\/journal.pone.0012776"},{"key":"1022_CR27","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. Omics. 2012;16:284\u20137.","journal-title":"Omics"},{"key":"1022_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2020.104956","volume":"142","author":"BT Casali","year":"2020","unstructured":"Casali BT, MacPherson KP, Reed-Geaghan EG, Landreth GE. Microglia depletion rapidly and reversibly alters amyloid pathology by modification of plaque compaction and morphologies. Neurobiol Dis. 2020;142:104956.","journal-title":"Neurobiol Dis"},{"key":"1022_CR29","doi-asserted-by":"crossref","unstructured":"Reilly AM, Tsai AP, Lin PB, Ericsson AC, Oblak AL, Ren H. Metabolic Defects Caused by High-Fat Diet Modify Disease Risk through Inflammatory and Amyloidogenic Pathways in a Mouse Model of Alzheimer's Disease. Nutrients.\u00a02020;12.","DOI":"10.3390\/nu12102977"},{"key":"1022_CR30","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1186\/s12974-020-02017-7","volume":"17","author":"HJ Greve","year":"2020","unstructured":"Greve HJ, Mumaw CL, Messenger EJ, Kodavanti PRS, Royland JL, Kodavanti UP, et al. Diesel exhaust impairs TREM2 to dysregulate neuroinflammation. J Neuroinflammation. 2020;17:351.","journal-title":"J Neuroinflammation"},{"key":"1022_CR31","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nmeth.2089","volume":"9","author":"CA Schneider","year":"2012","unstructured":"Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9:671\u20135.","journal-title":"Nat Methods"},{"key":"1022_CR32","doi-asserted-by":"crossref","unstructured":"Kleineidam L, Chouraki V, Prochnicki T, van der Lee SJ, Madrid-Marquez L, Wagner-Thelen H, Karaca I, Weinhold L, Wolfsgruber S, Boland A, et al. PLCG2 protective variant p.P522R modulates tau pathology and disease progression in patients with mild cognitive impairment. Acta Neuropathol.\u00a02020.","DOI":"10.1007\/s00401-020-02138-6"},{"key":"1022_CR33","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.3233\/JAD-200019","volume":"77","author":"C Olive","year":"2020","unstructured":"Olive C, Ibanez L, Farias FHG, Wang F, Budde JP, Norton JB, et al. Examination of the effect of rare variants in TREM2, ABI3, and PLCG2 in LOAD through multiple phenotypes. J Alzheimers Dis. 2020;77:1469\u201382.","journal-title":"J Alzheimers Dis"},{"key":"1022_CR34","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/mp.2017.246","volume":"23","author":"KE Hopperton","year":"2018","unstructured":"Hopperton KE, Mohammad D, Trepanier MO, Giuliano V, Bazinet RP. Markers of microglia in post-mortem brain samples from patients with Alzheimer\u2019s disease: a systematic review. Mol Psychiatry. 2018;23:177\u201398.","journal-title":"Mol Psychiatry"},{"key":"1022_CR35","doi-asserted-by":"crossref","unstructured":"Kaiser T, Feng G. Tmem119-EGFP and Tmem119-CreERT2 Transgenic Mice for Labeling and Manipulating Microglia. eNeuro.\u00a02019;6.","DOI":"10.1101\/624825"},{"key":"1022_CR36","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/neup.12235","volume":"36","author":"J Satoh","year":"2016","unstructured":"Satoh J, Kino Y, Asahina N, Takitani M, Miyoshi J, Ishida T, et al. TMEM119 marks a subset of microglia in the human brain. Neuropathology. 2016;36:39\u201349.","journal-title":"Neuropathology"},{"key":"1022_CR37","doi-asserted-by":"publisher","first-page":"23083","DOI":"10.1074\/jbc.M109.019265","volume":"284","author":"KL Everett","year":"2009","unstructured":"Everett KL, Bunney TD, Yoon Y, Rodrigues-Lima F, Harris R, Driscoll PC, et al. Characterization of phospholipase C gamma enzymes with gain-of-function mutations. J Biol Chem. 2009;284:23083\u201393.","journal-title":"J Biol Chem"},{"key":"1022_CR38","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/s41593-020-0650-6","volume":"23","author":"BJ Andreone","year":"2020","unstructured":"Andreone BJ, Przybyla L, Llapashtica C, Rana A, Davis SS, van Lengerich B, et al. Alzheimer's-associated PLCgamma2 is a signaling node required for both TREM2 function and the inflammatory response in human microglia. Nat Neurosci. 2020;23:927\u201338.","journal-title":"Nat Neurosci"},{"issue":"566-581","key":"1022_CR39","volume":"47","author":"S Krasemann","year":"2017","unstructured":"Krasemann S, Madore C, Cialic R, Baufeld C, Calcagno N, El Fatimy R, et al. The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity. 2017;47(566-581):e569.","journal-title":"Immunity"},{"key":"1022_CR40","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.cell.2017.05.018","volume":"169","author":"H Keren-Shaul","year":"2017","unstructured":"Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland TK, et al. A unique microglia type associated with restricting development of Alzheimer\u2019s disease. Cell. 2017;169:1276\u20131290.e1217.","journal-title":"Cell"},{"key":"1022_CR41","doi-asserted-by":"crossref","unstructured":"Tsai AP, Dong C, Lin PB, Messenger EJ, Casali BT, Moutinho M, Liu Y, Oblak AL, Lamb BT, Landreth GE, Bissel SJ, Nho K, et al. PLCG2 is Associated with the Inflammatory Response and is Induced by Amyloid Plaques in Alzheimer's Disease. BioProject, PRJNA801624, NCBI Sequence Read Archive 2022. https:\/\/www.ncbi.nlm.nih.gov\/geo\/query\/acc.cgi?acc=GSE195650.","DOI":"10.1186\/s13073-022-01022-0"}],"container-title":["Genome Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-022-01022-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13073-022-01022-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-022-01022-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T05:47:19Z","timestamp":1674798439000},"score":1,"resource":{"primary":{"URL":"https:\/\/genomemedicine.biomedcentral.com\/articles\/10.1186\/s13073-022-01022-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,18]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1022"],"URL":"https:\/\/doi.org\/10.1186\/s13073-022-01022-0","relation":{},"ISSN":["1756-994X"],"issn-type":[{"value":"1756-994X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,18]]},"assertion":[{"value":"9 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experimental procedures and animal care were approved by the Institutional American Association for Laboratory Animal Science Care and Use Committee (IACUC, protocol# 20007-MD\/R\/HZ and 18099-MD\/R\/HZ\/E\/AR) and performed in accordance with the Stark Neurosciences Research Institute Laboratory Animal Resource Center (LARC), Indiana University School of Medicine.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests. The stipend for A.P.T. was provided in part through a fellowship funded by Eli Lilly and Company; however, the project was not sponsored by Eli Lilly and Company and they had no influence on the design, conduct, or reporting of the research.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17"}}